Spectroscopy in Functional Assessment of Peripheral Artery Disease (spectroAMI) (NCT03723473) | Clinical Trial Compass
UnknownNot Applicable
Spectroscopy in Functional Assessment of Peripheral Artery Disease (spectroAMI)
France40 participantsStarted 2019-02-13
Plain-language summary
To explore the reliability of P-31 MR spectroscopy mitochondrial function in patients with peripheral arterial occlusive disease.
Who can participate
Age range18 Years – 70 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Peripheral arterial occlusive disease (PAOD) with claudication and surgery planning with proximal lesion (iliac or femoral (x-ray angiography or CT or MRA) and no distal lesions (doppler)
* ABI\<0.90 or \>1.30
* signed consent form
* health insurance coverage
Exclusion Criteria:
* Contraindication in the practice of MRI: pacemaker, metallic cardiac valve, intra-ocular metal part, claustrophobia
* critical ischemia \>15 days
* Type 1 or 2 diabetes
* weight \>200kg
* non stabilized hypertension
* beta-blockers
* non-atherosclerotic vascular occlusive disease (Buerger disease, Takayasu disease, venous disease, trapped popliteal artery etc..)
* Neurological pathology/non-voluntary contraction
What they're measuring
1
Muscle phosphocreatine (PCr) recovery time constant
Timeframe: During the MRI procedure
Trial details
NCT IDNCT03723473
SponsorCentre Hospitalier Universitaire de Saint Etienne